Mandy Jackson

I am Managing Editor, US Commercial News, for the Citeline Commercial publication Scrip. Views expressed here are strictly my own.

[Mandy Jackson @ScripMandy]

FDA concerns about PRC2 complex inhibition & potential secondary hematologic malignancies, with both EZH2- & EED-targeting, due to Ipsen’s Tazverik, ended Fulcrum’s pociredir development & now there’s a partial hold on 2 Daiichi Sankyo valemetostat trials. https://t.co/TA9rbN5cID

[Renaissance Capital @IPOtweet]

Cancer biotech Parabilis Medicines sets terms for $450 million IPO $PBLS $IPO #IPO https://t.co/G7FchwJhKw

[Sue Sutter @PinkSheetSutter]

SCOOP: $AMGN Fights @US_FDA On Tavneos Withdrawal Over Efficacy, Data Integrity Concerns https://t.co/rdaY0OD8Wo

[Mandy Jackson @ScripMandy]

This is some of the most valuable hantavirus information I’ve seen yet. And important to see in a region with many thousands of cruise ship visitors annually.

[SanDiegoCounty @SanDiegoCounty]

Hearing a lot about Hantavirus lately? While locally and in California, we don't see the Andes virus you're hearing about in the news, we monitor regularly for the Sin Nombre virus which does not spread person to person. More: https://t.co/WbLwvAnjdQ

[Renaissance Capital @IPOtweet]

Coagulation disorder biotech Hemab Therapeutics Holdings sets terms for $200 million IPO, pricing this week $COAG $IPO #IPO https://t.co/9kPm1ELvlM

[Mandy Jackson @ScripMandy]

Three $200m biotech IPOs expected to launch this week: Seaport, Avalyn, Hemab

[Renaissance Capital @IPOtweet]

US IPO Week Ahead: Biotechs, mining, and Bill Ackman deals set to debut $AVLN $COAG $SPTX $SBMT $PS $IPO #IPO https://t.co/wbf7Cn5DFg

[Renaissance Capital @IPOtweet]

Neuropsychiatric therapeutics Seaport Therapeutics sets terms for $201 million IPO, pricing this week $SPTX $IPO #IPO https://t.co/xWKAGymX0a

[Renaissance Capital @IPOtweet]

Pulmonary fibrosis biotech Avalyn Pharma sets terms for $201 million IPO $AVLN $IPO #IPO https://t.co/HS8rde0uLJ

[Renaissance Capital @IPOtweet]

Israel-based Phase 3 ocular diseases biotech Tarsier Pharma files for a $35 million US IPO $TARX $IPO #IPO https://t.co/lAozINFVyv

[Renaissance Capital @IPOtweet]

Coagulation disorder biotech Hemab Therapeutics files for a $100 million IPO $COAG $IPO #IPO https://t.co/b8iLVrT48U

[Renaissance Capital @IPOtweet]

Obesity biotech Kailera Therapeutics files for a $100 million IPO $KLRA $IPO #IPO https://t.co/WYoN43k6uy

[Mandy Jackson @ScripMandy]

$XBI is down 2.5% today and 0.7% year-to-date after the Fed held interest rates steady. It’s been a volatile year so far for biopharma after an optimistic start to 2025.

[Federal Reserve @federalreserve]

Federal Reserve issues #FOMC statement: https://t.co/WeFZMiZicH

[Mandy Jackson @ScripMandy]

The scariest consequence of climate change yet … 😬😳🐍 This assuages my guilt somewhat that it’s warmer here than almost anywhere in the US right now. Stay cool San Diego.

[The San Diego Union-Tribune @sdut]

San Diego County’s heat wave is making rattlesnakes more active and visible https://t.co/dM6HfSULhv

[Renaissance Capital @IPOtweet]

Asthma-focused AI biotech Generate Biomedicines sets terms for $400 million IPO $GENB $IPO #IPO https://t.co/qVqjMb2Yh6

[Renaissance Capital @IPOtweet]

Immuno-responsive cancer biotech Eikon Therapeutics prices upsized IPO at $18 high end $EIKN $IPO #IPO https://t.co/dhntvLjozi

[Renaissance Capital @IPOtweet]

Hair loss biotech Veradermics prices upsized IPO at $17, above the range $MANE $IPO #IPO https://t.co/pSpStCNvER

[Mandy Jackson @ScripMandy]

Does anyone have good suggestions for organizations or advocacy groups that can offer advice on options for assisted living or group home care for elderly, disabled couples, including a veteran, who would not meet low income standards but also are not wealthy?

[Mandy Jackson @ScripMandy]

Three #biopharma IPOs on deck for next week.

[Renaissance Capital @IPOtweet]

US IPO Week Ahead: At least 7 sizable IPOs teed up in one of the busiest weeks in four years $MANE $BOBS $EIKN $FPS $LFTO $IPO #IPO https://t.co/m7v9O7WvC2

[Renaissance Capital @IPOtweet]

Immuno-responsive cancer biotech Eikon Therapeutics sets terms for $300 million IPO $EIKN $IPO #IPO https://t.co/zcJ0e4VaB5

[Renaissance Capital @IPOtweet]

BioVie liver disease carve-out Option Therapeutics files and sets terms for a $25 million IPO $OPTN $IPO #IPO https://t.co/wmMU2MNiwj